NASDAQ · ADXN
Addex Therapeutics Ltd
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ADXN: Dec 3, 2026
Addex Therapeutics Ltd American Depositary Shares is estimated to report earnings on 12/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.5.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool- Fintel · Oct 29, 7:33 AM EDTAddex Therapeutics Ltd Increases Issued Share Capital to Create Treasury SharesAddex Therapeutics Ltd announced that 93,000,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, which were issued from the company's capital band, are listed on the
- RTTNews · Oct 8, 7:42 AM EDTAddex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial(RTTNews) – Addex Therapeutics (ADXN) announced that its spin-out company Neurosterix has completed Phase 1 clinical studies of NTX-253, an investigational positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for schizophrenia.
- RTTNews · Oct 2, 4:06 AM EDTAddex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix(RTTNews) – Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, on Friday announced the appointment of Jean-Phillippe Rocher as the Head of Pharmaceutical Development, and a member of the Executive Management.
- The Motley Fool · Sep 28, 10:43 PM EDTAddex (ADXN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Sep 28, 4:44 AM EDTAddex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program(RTTNews) – Addex Therapeutics Ltd. (ADXN, ADXN.SW) on Monday reported a wider net loss for the first half, while operating loss narrowed from last year on lower research and development expenses.
- RTTNews · Sep 28, 4:37 AM EDTAddex Posts Narrower Loss In Q2(RTTNews) – Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company, released its second-quarter 2026 financial results on Monday and provided corporate updates for the quarter.
- RTTNews · Sep 24, 11:11 AM EDTCan Addex Therapeutics Maintain Its Cost-Cutting Momentum In Q2?(RTTNews) – Addex Therapeutics (ADXN) is scheduled to report its second-quarter and first-half 2026 financial results on September 28, 2026, with investors likely to focus on the company's financial position, pipeline progress and developments surrounding its Neurosterix spin-out
- RTTNews · Aug 26, 4:44 AM EDTAddex Therapeutics Secures $2.8 Mln Via ATM Sale; Cash Runway Extended To Q4 2027;Stock Up(RTTNews) – Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced that it has raised gross proceeds of $2.8 million through the sale of 0.44 million American Depositary Shares (ADS) representing 52.54 million shares under its At-the-Market (ATM) offerin
- RTTNews · Jul 8, 5:39 AM EDTAddex Research Highlights MGlu7 Modulation As A Novel Pathway In Sleep And Stress Regulation(RTTNews) – Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly influe
- RTTNews · Jun 25, 2:11 AM EDTAddex Records Wider Net Loss Of $1.7 Mln; Advances NTX-253 In Phase 1 For Schizophrenia(RTTNews) – Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Friday announced first quarter financial results, noting a net loss due to reduced incomes.
- RTTNews · Apr 30, 7:14 AM EDTAddex Reports Income Of CHF 0.2 Mln In 2025, Highlights Advances In Drug Development(RTTNews) – Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Thursday announced the full year financial results for 2025 and provided updates on corporate activities and drug development.
- RTTNews · Apr 23, 10:51 AM EDTAddex Reports Neurosterix On Track To Complete Phase 1 Trial For Schizophrenia Drug NTX-253(RTTNews) – Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, announced on Wednesday that the Phase 1 trial for NTX-253 in treating schizophrenia, developed by spun-out company Neurosterix, is on track to conclude by the second quarter of 2026.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Addex Therapeutics Ltd from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.